Online inquiry

IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7601MR)

This product GTTS-WQ7601MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF3R gene. The antibody can be applied in Neutropenia research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000760.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1441
UniProt ID Q99062
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7601MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8122MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ742MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AAB-001
GTTS-WQ4553MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ4617MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ11487MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ4686MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ4468MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ11956MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MLTA3698A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW